ASP-II: Ancrod Stroke Program: Ancrod (Viprinexâ„¢) for the Treatment of Acute, Ischemic Stroke
Phase 3
Terminated
- Conditions
- StrokeCerebral IschemiaBrain Infarction
- Interventions
- Biological: Ancrod (Viprinex)Drug: Placebo
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Neurobiological Technologies
- Target Recruit Count
- 311
- Registration Number
- NCT00300196
- Locations
- 🇺🇸
Manatee Memorial Hospital, Bradenton, Florida, United States
🇺🇸Bradenton Research Center, Bradenton, Florida, United States
🇺🇸Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States
Ancrod (Viprinexâ„¢) for the Treatment of Acute, Ischemic Stroke
Phase 3
Terminated
- Conditions
- Brain InfarctionStrokeCerebral Ischemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Neurobiological Technologies
- Target Recruit Count
- 277
- Registration Number
- NCT00141011
- Locations
- 🇺🇸
Loma Linda University School of Medicine, Loma Linda, California, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
🇺🇸Elkhart Clinic, LLC - Neurology, Elkhart, Indiana, United States
© Copyright 2025. All Rights Reserved by MedPath